Session 1  Controversies in biologics
Chair  Prof Zamir Halperin, The Tel Aviv Sourasky Medical Center
Prof Shimon Reif, Hadassah Medical Center
9:15-9:45  “Aggressive treatment up-front: are we there yet and which patients to choose”
Prof Bill Sandborn, San Diego
9:45-10:05  “Top down in pediatrics: more aggressive disease versus longer future disease duration”
Dr Richard Russell, Glasgow
10:05-10:25  “Opinion: The Step-up approach should be practiced”
Prof Shimon Bar Meir, The Sheba Medical Center Tel Hashomer
10:25-10:50  “When all anti-TNF fail...”
Prof Yehuda Chowers, Rambam Health Care Campus

Session 2  Surgery in IBD
Chair  Prof Petachia Reissman, Shaare Zedek Medical Center
Dr Hagith Nagar, Shaare Zedek Medical Center
11:10-11:25  DEBATE “Patients should be considered for early surgical intervention in both UC and Crohn’s”
Prof Barry Salky, New York
11:25-11:40  DEBATE “Patients should be generally referred to surgery after failing all medical therapies in IBD”
Dr Iris Dotan, The Tel Aviv Sourasky Medical Center
11:40-11:45  Voting
11:45-12:05  A state of the art lecture “The laparoscopic surgery in IBD”
Prof Barry Salky, New York

Session 3  Case-based discussion
Moderator  Dr. Dan Turner, Shaare Zedek Medical Center
Panel   Prof Bill Sandborn, Prof Mark Silverberg, Dr Richard Russell, Prof Barry Salky, Dr Eran Israeli, Prof Arie Levine
12:05-12:25  Dr Raffi Lev Zion
12:25-12:45  Dr Ariella Shitrit
12:45-13:05  Dr Tomer Adar

Session 4  Back to basics
Chair  Prof Rami Elhayek, The Chaim Sheba Medical Center at Tel Hashomer
Prof Reuven Shapiro, The Schneider Children’s Medical Center
13:45-14:25  “Genetics and beyond in IBD”
Prof Mark Silverberg, Toronto
14:25-14:55  “Treating the whole patient: the social and psychological implications of IBD”
Prof Marc Reissman
14:55-15:25  “How to optimize conventional therapy before moving to biologics in IBD?”
Dr Richard Russell
15:25-15:55  “Gut microbes: from early development to IBD (Pediatrics and early onset IBD)”
Dr Eytan Wine, Edmonton

16:05-16:50  A state of the art lecture “Novel therapies – tofacitinib, vedolizumab, anti-integrins, ustekinumab and others”
Prof Bill Sandborn San Diego